Attralus
Health Care · Biologics & Biosimilars
$197.6Mtotal raised · 4 rounds on record
$56Mlatest round · Venture round · Jan 2024 · 2 yr ago
1backers · venBio Partners
30stories in the press
Overview
Attralus is focused on advancing new solutions for amyloidosis therapy. The team has deep experience in Amyloid research and therapeutic development.
Funding and backers
Total raised
$197.6M
4 rounds on record
Latest round
$56M
Venture round · Jan 2024 · 2 yr ago
Backers
1
venBio Partners
The money's age
Long since its last round
33 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 26, 2024
Raised a round Venture round $56M · SEC Form D
Aug 31, 2021
Raised a round Venture round $116.6M · SEC Form D
Sep 14, 2020
Raised a round Series A $25M · Timmerman Report
Dec 13, 2019
Took on debt financing $175k · SEC Form D
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jan 2024 | $56M | — | SEC Form D |
| Venture round | Aug 2021 | $116.6M | — | SEC Form D |
| Series A | Sep 2020 | $25M | — | Timmerman Report |
| Debt Financing | Dec 2019 | $175k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Attralus, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Benson FongExecutive OfficerSEC Form D
Greg BellExecutive OfficerSEC Form D
Spencer GuthrieExecutive OfficerSEC Form D
Mark TimneyExecutive Officer, DirectorSEC Form D
Jonathan WallExecutive OfficerSEC Form D
Mehdi KhodadadExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing…
We partner with top biopharmaceutical companies and research institutions to discover and advance novel therapeutics.
Explore Therapeutic Protein Libraries. For decades, therapeutic antibody discovery and optimization has been a shot in the Dark With the…
EnteroBiotix is a clinical-stage biopharmaceutical company developing best-in-class full-spectrum microbial therapeutics.
Caedo Oncology AS develops new strategies for monoclonal anti-body based therapy. Learn more about our research and how we work.
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key…
People
Benson Fong
Executive Officer
Greg Bell
Executive Officer
Spencer Guthrie
Executive Officer
Mark Timney
Executive Officer, Director
Jonathan Wall
Executive Officer
Mehdi Khodadad
Executive Officer
Glen Firestone
Executive Officer
Gregory Bell
Executive Officer
James Testa
Executive Officer
Scientific Advisory
Directors
Rahul Kakkar
Director
Jake Bauer
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
venBio PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
NAPLES, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administ
Read more
Report
Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
PDF Version NAPLES, Fla., August 12, 2026 - Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administrati
Read more
Report
Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
PDF Version NAPLES, Fla., June 4, 2026- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administration (
Read more
Report
Bayer Expands Into Molecular Imaging With Acquisition Of Attralus Pan-Amyloid Radiotracers
Bayer has signed definitive agreements to acquire two investigational molecular imaging agents from Attralus, Inc., moving the company into the diagnostic tracer space as it looks to broaden its molecular imaging footprint and strengthen its cardiovascula
Read more
Report
Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
Attralus is focused on improving diagnosis & treatment in systemic amyloid diseases with cutting-edge imaging and therapeutic medicine.
Read more
Report
Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL amyloidosis
Click Here to View Presentation The post Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL amyloidosis appeared first on Attralus.
Read more
Report
Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
PDF Version Initial results of a Phase 1 / 2 open label study of AT-02, the company's lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented at ASH. The presentation includes data on AL patients in hematological
Read more
Report
Accurate Quantitation of Cardiac Amyloidosis by 124I-Evuzamitide Compared to Extracellular Volume
Click Here to View Poster The post Accurate Quantitation of Cardiac Amyloidosis by 124I-Evuzamitide Compared to Extracellular Volume appeared first on Attralus.
Read more
Report
Exploring cardiac uptake of the SPECT radiotracer, 99mTc-p5+14 (AT-05), in patients with amyloidosis - Significant correlations exist between structural or functional parameters and signal-to-background measurements.
Click Here to View Poster The post Exploring cardiac uptake of the SPECT radiotracer, 99mTc-p5+14 (AT-05), in patients with amyloidosis - Significant correlations exist between structural or functional parameters and signal-to-background measurements. app
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
South San Francisco
United States
HQ
Naples
United States
Regional office
Follow
365 Fifth Ave South, Ste 208, Naples, FL 34102